Track record · closed signal

Novavax Inc (NVAX) — closed signal from May 5, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 3, 2026 — -8.4% at the close.

Predicted vs. what happened

NVAX price · publication thesis → realized outcomesplit-adjusted

$7.50 – $8.20Entry zone — fair-value band

$8.09Published — price the day we called it

$10.36Target — the price the thesis aimed for

$11.61Peak — highest point inside the window, not a realized return

$7.41Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 3 days.

At window close

-8.4%

realized, from the publication price to the last close inside the window

Peak gain

+43.4%

peak, from the publication price — not a realized return

S&P 500, same window

+5%

SPY over the identical days, dividend-adjusted

Window close

$7.41

last close inside the window, ended August 3, 2026

Peak price

$11.61

peak on May 27, 2026 — not a realized return

Days to target

The thesis — published May 5, 2026

Predicted growth

+28%

over the measurement window

Target price

$10.36

the price the thesis aimed for

Entry zone

$7.50 – $8.20

the fair-value band we waited for

Price at publication

$8.09

published May 5, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novavax's recent shift toward licensing and partnerships with big drugmakers gives a clear chance for big upside if vaccine data and upcoming earnings go well. The company has cash and looks reasonably valued, but biotech results and heavy short interest make outcomes very uncertain. Near-term results are speculative and likely to cause big price swings.

Primary drivers

Licensing deals could make revenue steadier and more reliable
Deals with Sanofi and Pfizer boost credibility and reach
Earnings and vaccine trial updates can move the stock quickly
Cash on hand reduces the chance of forced financing

How it played out

NVAX: target reached in 3 days

Lyra published a short-term thesis for NVAX at $8.09, expecting 28% growth toward $10.36. The thesis pointed to steadier licensing revenue, deals with Sanofi and Pfizer, earnings and vaccine trial updates, and cash on hand as protection against forced financing. It also called the setup speculative because biotech results and heavy short interest could produce large price swings.

Inside the window, NVAX reached the $10.36 target in 3 days. It later peaked at $11.61 on May 27, a 43.4% gain from publication. By August 3, it had fallen to $7.41. The target was reached quickly and the peak exceeded it, even though the stock ended below the published entry zone. The thesis played out within the measured period.

What happened during the window

On May 6, 2026, Novavax reported first-quarter total revenue of $140 million and reiterated its 2026 revenue framework.

Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVAX signals